Part III: Mastering the Protocols for Hormone Replacement Therapy - Complex Cases - May 2018

Course Details


This course has been approved for21 AMA PRA Category 1 Credits, 21 Nursing Contact Hours (21 pharmacologic hours), 21 Hours Pharmacy Credit (knowledge based).
Prerequisites: Part I and II

Course Description: The educational process for Part III is both didactic and interactive with maximum audience participation. All of the most complex, interesting, and confusing cases experienced by Dr.Rouzier over the last ten years are presented. The participants decide on the corrective management with literature reviews to guide therapy. Be forewarned, as in the past, many concepts taught in other academies are contrary to the medical literature presented in this course. The attendee will decide therapy based on evidence based guidelines rather than public opinion. Although there are no medical boards for this type of practice, Part III is similar to a medical board that digs deeper into the complexities of age management medicine. Clinical cases will be analyzed to formulate appropriate treatments and management to improve the understanding and level of care provided to patients. In Parts I & II the cases and studies are simple and straightforward. However, a thorough understanding of Parts I and II are necessary to understand many of the complex cases presented in Part III. Due to the many different hormones, different studies, different age groups, and misleading and incorrect journalistic conclusions, it is quite difficult for the practitioner to understand and defend their practice of HRT. Extensive literature summaries that provided credence and support will be presented so that the practitioner has all available data to defend why we do what we do. Studies will be presented that demonstrate more cancer caused by standard statin treatments for cholesterol than by PremPro®. Progesterone causes decreased absorption of estrogen yet it can be anticipated and prevented. Most patients have very low Vitamin D levels (which are harmful), yet most doctors don’t know how to optimally treat and monitor. Differentiation between adrenal hyperplasia and PCOS is important, as well as understanding treatment of thin women vs. obese women and how it will affect future morbidity. It is also important to understand when women require transdermal vs. oral estrogen. The risk of prostate cancer decreases for every doubling of estradiol level or SHBG level, in spite of some academies preaching the need to lower estrogen and SHBG. Also contrary to EBM, these same academies teach the use of progesterone to protect the prostate whereas the evidence demonstrates a potential increase in prostate cancer by progesterone administration to men. Finally, estrogen’s effect on lipids and SHBG are what is most protective against CVD which is provided only by oral estrogen and not transdermal. Each of these topics will be thoroughly addressed.


Workshop Schedule

  • Friday, 8:00 a.m. - 6:00 p.m.
  • Saturday, 8:00 a.m. - 6:00 p.m.
  • Sunday, 8:00 a.m. - 12:00 noon

  • Where

  • Hyatt Regency Houston Galleria
    2626 Sage Rd.
    Houston, Texas 77056

Outlook Outlook
iCal iCal
Google Google
Yahoo! Yahoo!